KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortization of Deferred Charges (2016 - 2022)

Historic Amortization of Deferred Charges for Travere Therapeutics (TVTX) over the last 9 years, with Q4 2022 value amounting to $428000.0.

  • Travere Therapeutics' Amortization of Deferred Charges fell 8516.98% to $428000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.6 million, marking a year-over-year decrease of 8557.2%. This contributed to the annual value of $1.7 million for FY2024, which is 40.75% up from last year.
  • As of Q4 2022, Travere Therapeutics' Amortization of Deferred Charges stood at $428000.0, which was down 8516.98% from $428000.0 recorded in Q3 2022.
  • In the past 5 years, Travere Therapeutics' Amortization of Deferred Charges ranged from a high of $2.9 million in Q4 2021 and a low of $325000.0 during Q2 2018
  • Its 5-year average for Amortization of Deferred Charges is $1.9 million, with a median of $2.5 million in 2019.
  • In the last 5 years, Travere Therapeutics' Amortization of Deferred Charges soared by 113367.35% in 2018 and then tumbled by 8765.07% in 2022.
  • Travere Therapeutics' Amortization of Deferred Charges (Quarter) stood at $2.4 million in 2018, then increased by 3.64% to $2.5 million in 2019, then increased by 7.3% to $2.7 million in 2020, then rose by 7.33% to $2.9 million in 2021, then tumbled by 85.17% to $428000.0 in 2022.
  • Its last three reported values are $428000.0 in Q4 2022, $428000.0 for Q3 2022, and $428000.0 during Q2 2022.